Table 1

Baseline demographics

Number of patients

786

Age (mean ± SD years; range)

67 ± 12 (27-92)

Male/female (%)

73/27

Underlying liver disease (%)

HBsAg-positive

393 (50)

HBsAg-negative

Anti-HCV-positive

265 (34)

Anti-HCV-negative

128 (16)

Tumoral characteristics (%)

Single lesion

500 (64)

Multi-nodular lesions

286 (36)

Maximal tumor diameter

≤ 5 cm

566 (72)

>5 cm

220 (28)

Ascites (%)

Yes

101 (13)

No

685 (87)

Serum AFP level (ng/mL) (%)

Median (range)

29 (2-10,032,600)

<20

344 (44)

20 - 400

288 (37)

>400

154 (19)

Performance status (%)

ECOG scale 0

590 (75)

ECOG scale 1-3

196 (25)

Serum biochemistries (mean ± SD)

Albumin (g/dL)

3.7 ± 0.6

Bilirubin (mg/dL)

1.1 ± 1.0

Creatinine (mg/dL)

1.3 ± 3.2

Prothrombin time INR

1.1 ± 0.3

ALT (IU/L)

69 ± 68

AST (IU/L)

52 ± 44

Child-Pugh-Turcotte class (%)

A

639 (81)

B

147 (19)

MELD score (mean ± SD; range) (%)

9.3 ± 3.1 (6.4-23.9)

<8

336 (43)

8-11

215 (27)

>11

235 (30)

Vascular invasion (%)

No

699 (9)

Yes

87 (91)

CLIP staging (%)

Score 0

266 (34)

Score 1

276 (35)

Score 2

141 (18)

Score 3

66 (8)

Score 4 or 5

37 (5)

Total tumor volume (cm3) (%)

Mean ± SD (range)

177 ± 436 (0.1-3,591)

Median

21

<10

297 (38)

10-50

226 (29)

50-200

121 (15)

200-500

57 (7)

>500

85 (11)

Treatment (%)

PAI or PEI

79 (10)

RFA

221 (28)

TACE

471 (60)

More than one methods

15 (2)


Huo et al. BMC Gastroenterology 2010 10:146   doi:10.1186/1471-230X-10-146

Open Data